Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.06
10.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Tonghua Dongbao Pharmaceutical Co Ltd
Change in Working Capital
Tonghua Dongbao Pharmaceutical Co Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
|
Change in Working Capital
-¥1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Change in Working Capital
-¥332.3m
|
CAGR 3-Years
26%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Change in Working Capital
-¥1.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
-16%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Change in Working Capital
-¥16.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Change in Working Capital
-¥5.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Change in Working Capital
-¥1.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tonghua Dongbao Pharmaceutical Co Ltd
Glance View
Nestled in the bustling heart of China's pharmaceutical industry, Tonghua Dongbao Pharmaceutical Co., Ltd. has carved out a distinctive niche in the world of diabetes care. Since its inception, the company has been focused on developing, manufacturing, and distributing a range of innovative pharmaceutical products, primarily concentrating on insulin products. With its headquarters strategically located in Tonghua City—a region known for its rich medicinal resources—the company integrates advanced biotechnological processes with traditional pharmaceutical practices. Tonghua Dongbao’s competitive edge lies in its ability to harness cutting-edge technology to produce high-quality insulin products efficiently, allowing it to tap into the rapidly growing domestic and international markets. As diabetes continues to be a major global health challenge, this focus on insulin has positioned the company as a critical player in the fight to manage and treat this chronic disease. Their revenue model is underscored by a keen focus on the production of insulin and its analogs, which represent a significant portion of its sales. Beyond insulin, Tonghua Dongbao also produces a range of other pharmaceuticals, contributing to a diversified product portfolio that supports steady revenue streams. Importantly, the company’s investment in R&D has led to a robust pipeline of new and improved therapeutics aimed at expanding their reach and maintaining competitive advantage. Through strategic partnerships and collaborations, both within China and internationally, Tonghua Dongbao continues to amplify its market presence. In doing so, it exemplifies a commitment not only to financial growth but also to advancing healthcare outcomes for millions of diabetes patients around the globe.
See Also
What is Tonghua Dongbao Pharmaceutical Co Ltd's Change in Working Capital?
Change in Working Capital
-1.2B
CNY
Based on the financial report for Sep 30, 2024, Tonghua Dongbao Pharmaceutical Co Ltd's Change in Working Capital amounts to -1.2B CNY.
What is Tonghua Dongbao Pharmaceutical Co Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
-10%
Over the last year, the Change in Working Capital growth was -17%.
You don't have any saved screeners yet
